NavDx for HPV Positive (Head and Neck and Anal) Cancers
Human papillomavirus (HPV) is a major causative agent for oropharyngeal squamous cell carcinoma (OPSCC), now surpassing cervical cancer in incidence. OPSCC often arises from chronic HPV infection localized to the tonsils and other oropharyngeal lymphoid tissues. Traditional HPV DNA detection cannot differentiate benign infection from malignant transformation.
NavDx offers a non-invasive, blood-based liquid biopsy that detects circulating tumor tissue-modified viral (TTMV)-HPV DNA, a biomarker associated specifically with HPV-driven malignancy. Studies have shown that TTMV-HPV DNA is present in >90% of patients with HPV-driven OPSCC. Elevated TTMV-HPV DNA levels predict higher risk of locoregional recurrence and distant metastasis within three years of initial diagnosis. The test is designed to distinguish HPV infection from HPV-driven tumorigenesis, assess therapeutic response, and monitor molecular residual disease (MRD).
- Early identification of malignant transformation in HPV-positive patients
- Surveillance for therapeutic response and disease recurrence
- Monitoring molecular residual disease following treatment
Negative results (not detected) for TTMV-HPV DNA indicate low likelihood of active HPV-driven malignancy.
Positive results or presence of TTMV-HPV DNA indicate active malignancy or risk of recurrence. Higher quantitative levels correlate with greater disease burden or progression risk. Quantitative values (% positivity) should be interpreted in conjunction with clinical, imaging, and pathological findings.
Negative: Below assay-specific cutoff (cutoff values established by the performing laboratory)
Whole blood (EDTA tube).
Stability
- Refrigerated: 14 days
Do not freeze.
- Diagnostics (Basel). 2023 Feb 14;13(4):725. [PMID: 36832208]
- JAMA Otolaryngol Head Neck Surg. 2022 Dec 1;148(12):1120-1130. [PMID: 36301568]
- J Clin Oncol. 2023 Sep 20;41(27):4449. [PMID: 32017652]
- Cancer. 2022 Jun 1;128(11):2193-2204. [PMID: 35139236]
- Int J Cancer. 2022 Oct 1;151(7):1081-1085. [PMID: 35262203]
- Clin Cancer Res. 2022 Oct 3;28(19):4292-4301. [PMID: 35576437]